Alzheimer’s brain decline slashed in half by ‘thrilling’ new drug: trial
AI Image

Alzheimer’s brain decline slashed in half by ‘thrilling’ new drug: trial

New York Post • • business

Key Points:

  • A new experimental drug, low-dose diranersen, demonstrated a 54% slower decline in memory and thinking over nearly two years in Alzheimer's patients, suggesting it could be more effective than existing therapies.
  • Diranersen is the first drug to show a reduction in tau protein, which forms harmful brain tangles linked to Alzheimer's, by using gene-silencing technology to block RNA signals that produce tau.
  • Researchers, including experts from Harvard Medical School and UCSF, described the trial results as "thrilling" and "highly encouraging," noting the drug's potential to meaningfully slow disease progression and preserve patient independence.
  • A larger phase three trial is planned to confirm these findings, with UK recruitment beginning in the spring, while some side effects like headaches and confusion were reported, particularly at higher doses.
  • With over seven million Americans currently affected and numbers expected to nearly double by 2050, diranersen could represent a major breakthrough in Alzheimer's treatment if further trials prove successful.

Trending Business

Trending Technology

Trending Health